Catheter Precision (VTAK) Long-Term Deferred Tax (2022 - 2023)
Catheter Precision's (VTAK) quarterly Long-Term Deferred Tax came in at $26.8 million in Q4 2023, up 207.88% year-over-year from $8.7 million in Q4 2022, and up 207.88% quarter-over-quarter from $8.7 million in Q4 2022.
Powered by 
Analysis
Catheter Precision (VTAK) Long-Term Deferred Tax (2022 - 2023) Analysis & Trends
Catheter Precision (VTAK) has reported Long-Term Deferred Tax for 2 consecutive years, with $26.8 million the latest figure, recorded in Q4 2023.
- On a quarterly basis, Long-Term Deferred Tax rose 207.88% year-over-year to $26.8 million in Q4 2023; TTM through Dec 2023 was $26.8 million, a 207.88% increase from a year earlier, with the FY2023 full-year figure at $26.8 million, up 207.88% from the prior year.
- Long-Term Deferred Tax was $26.8 million for Q4 2023 at Catheter Precision, up from $8.7 million in the prior quarter.
- Over five years, Long-Term Deferred Tax peaked at $26.8 million in Q4 2023 and troughed at $8.7 million in Q4 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.04 Bn | 177.44 Bn | 7.27 Bn |
| 2 | Intuitive Surgical | 125.02 Bn | 119.81 Bn | 1.96 Bn |
| 3 | Medtronic | 117.84 Bn | 109.02 Bn | 6.34 Bn |
| 4 | Stryker | 105.50 Bn | 102.02 Bn | 4.50 Bn |
| 5 | Boston Scientific | 66.27 Bn | 65.73 Bn | 3.85 Bn |
| 6 | Edwards Lifesciences | 49.60 Bn | 45.35 Bn | 1.35 Bn |
| 7 | Alcon | 33.70 Bn | 32.24 Bn | 1.68 Bn |
| 8 | Dexcom | 32.06 Bn | 30.11 Bn | 830.00 Mn |
| 9 | Steris | 21.02 Bn | 20.54 Bn | 684.20 Mn |
| 10 | Catheter Precision | 480,427.59 | -1.36 Mn | 98,000.00 |